Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of [14C]-etrumadenant in healthy male subjects
NL-OMON51599Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etrumadenant in cancer, sponsored by Arcus Biosciences. Primary endpoints: Time course of excretion of total radioactivity in urine and feces, Recovery of total radioactivity (mass balance) and 2 more. Started May 2022; status: completed.
02
Drugs
etrumadenant
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON51599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51599.